Abstract:Osteoporosis is a serious health problem worldwide. Semaphorins (Sema) have been described as key molecules involved in the cross-talk between bone cells (osteoblasts/osteoclasts). In this study, we investigated whether plasmid containing Sema3a could ameliorate bone loss in an ovariectomized (OVX) mouse model via (AspSerSer)6, a selectively bone-targeting moiety. Plasmid pcDNA3.1(+)-Sema3a-GFP was fabricated and transfected cells with the plasmid demonstrated statistically higher levels of Sema3A in vitro (p < 0.001). Mice were ovariectomized and injected twice weekly with (AspSerSer)6-(STR-R8)+pcDNA3.1(+)-Sema3a-GFP for four weeks. The aim of the study was twofold: firstly to design an effective bone-targeting drug-delivery system (AspSerSer)6. Secondly, the effects of Sem3A gene therapy on bone loss was investigated. Here, the targeting selectivity of pcDNA3.1(+)-Sema3a-GFP via (AspSerSer)6 to the trabecular bone surface was firstly verified by histological observation of frozen sections and immunofluorescence staining. Then, bone microstructure analysis by Micro-CT indicated significantly less bone loss in mice treated with (AspSerSer)6-(STR-R8)+pcDNA3.1(+)-Sema3a-GFP compared to the control group (p < 0.05). Furthermore,H&E staining and Safranin O staining of the decalcified sections demonstrated statistically significantly higher bone area/total area in the mice that were injected with (AspSerSer)6-(STR-R8)+pcDNA3.1(+)-Sema3a-GFP (p < 0.001, p < 0.01,respectively). TRAP staining and immunohistochemistry staining of COL I demonstrated lower numbers of osteoclasts and significantly increased numbers of osteoblasts in the bone-targeting moiety delivering pcDNA3.1(+)-Sema3a-GFP group, when compared to the control group (p < 0.01, p < 0.001,respectively). Together, our findings have identified that, (AspSerSer)6, a bone-targeting drug-delivery system based on semaphorin3A gene therapy, ameliorated bone loss in osteoporotic ovariectomized mice, by suppressing osteoclastic bone resorption and simultaneously increasing osteoblastic bone formation. Gene therapy by local site-specific Sema3A overexpression might be a potential new strategy for treating osteoporosis and bone defects.

Semaphorin 3A enhances osteogenesis of MG63 cells through interaction with Schwann cells in vitro.

Semaphorinï¿½3A Enhances Osteogenesis of MG63 Cells Through Interaction with Schwann Cells Inï¿½vitro

Peripheral nerve‐derived Sema3A promotes osteogenic differentiation of mesenchymal stem cells through the Wnt/β‐catenin/Nrp1 positive feedback loop

Semaphorin 3A promotes the osteogenic differentiation of rat bone marrow-derived mesenchymal stem cells in inflammatory environments by suppressing the Wnt/β-catenin signaling pathway

Semaphorin 3A: A new player in bone remodeling.

Sema3A Inhibits Osteolytic Bone Metastasis of Non-small Cell Lung Cancer

Sema3A secreted by sensory nerve induces bone formation under mechanical loads

Bioactive semaphorin 3A promotes sequential formation of sensory nerve and type H vessels during in situ osteogenesis

Semaphorin3B Promotes Proliferation and Osteogenic Differentiation of Bone Marrow Mesenchymal Stem Cells in a High-Glucose Microenvironment

Semaphorin 3E promote Schwann cell proliferation and migration

Effects of Semaphorin3A on the Growth of Sensory and Motor Neurons.

The Role of Semaphorin 3A in Bone Remodeling

Silicified collagen scaffold induces semaphorin 3A secretion by sensory nerves to improve <i>in-situ</i> bone regeneration

Sustained Release of Semaphorin 3A from Α-Tricalcium Phosphate Based Cement Composite Contributes to Osteoblastic Differentiation of MC3T3-E1 Cells

A bone-targeting drug-delivery system based on Semaphorin 3A gene therapy ameliorates bone loss in osteoporotic ovariectomized mice.

Prostate cancer cells induce osteoblastic differentiation via semaphorin 3A.

Interaction between Schwann cells and osteoblasts in vitro

The role of semaphorin 3A on chondrogenic differentiation

Expression of Semaphorin-3A and its receptors in endochondral ossification: potential role in skeletal development and innervation

The Role of Semaphorin 3A in the Skeletal System

Schwann Cells Accelerate Osteogenesis via the Mif/CD74/FOXO1 Signaling Pathway In Vitro